HHS Will Buy More Paxlovid, Offer Free Access During Commercialization, Drug-Pricing Advocate Wary

HHS has agreed to buy more Paxlovid so it can continue providing Medicare, Medicaid and uninsured individuals free access after the COVID-19 antiviral soon transitions to the commercial market, but a consumer advocate notes the government hasn’t disclosed how much it will pay for the new product and the agreement doesn’t prevent Pfizer hiking commercial prices. The additional terms added to the agreement state HHS can continue ordering Paxlovid until Dec. 15 of this year, with a guarantee that future...